INFI - Infinity Pharmaceuticals Inc.

INFI Stock Chart

INFI Profile

Infinity Pharmaceuticals, Inc., a prominent biopharmaceutical firm based in Cambridge, Massachusetts, specializes in the development of innovative therapies aimed at combating cancer. The company's flagship product candidate, IPI-549, is a clinical-stage immuno-oncology treatment administered orally. It targets phosphoinositide-3-kinase-gamma, currently undergoing Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors.

Infinity Pharmaceuticals maintains strategic alliances with key players in the pharmaceutical industry to bolster its research and development efforts. These partnerships include collaborations with Intellikine, Inc., focusing on pharmaceuticals targeting PI3K delta and/or gamma isoforms, and Verastem, Inc., for the research, development, commercialization, and manufacturing of duvelisib and related products. The company also collaborates with PellePharm, Inc., advancing its hedgehog inhibitor program with IPI-926, a clinical-stage candidate.

Additionally, Infinity Pharmaceuticals has established collaboration agreements with industry giants such as Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. These collaborations underscore the company's commitment to advancing groundbreaking therapies and expanding its pipeline of oncology treatments.

Founded in 1995, Infinity Pharmaceuticals continues to drive innovation in the biopharmaceutical sector, leveraging its expertise in oncology to pioneer new approaches in cancer treatment. The company remains at the forefront of research and development, dedicated to improving outcomes for patients worldwide battling various forms of cancer.

INFI Revenue Chart

INFI Earnings

Analyst Ratings